Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of 12-O-tetradecanoylphorbol-13-acetate in patients with relapsed or refractory hematologic malignancies/bone marrow disorders

Next Previous
X
Search
Trial Profile

Phase I study of 12-O-tetradecanoylphorbol-13-acetate in patients with relapsed or refractory hematologic malignancies/bone marrow disorders

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tetradecanoylphorbol acetate (Primary)
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Ovarian disorders; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma; Squamous cell cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 23 Feb 2015 According to a Rich Pharmaceuticals media release, the results of this trial were published in Cancer Chemotherapy and Pharmacology.
    • 02 Feb 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 21 Dec 2005 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top